Keywords
Last Name

Elaine M. Hylek, MD

TitleProfessor
InstitutionBoston University School of Medicine
DepartmentMedicine
DivisionGeneral Internal Medicine
Address801 Massachusetts Ave Crosstown Center
Boston MA 02118
Phone(617) 414-3743
ORCID ORCID Icon0000-0001-8263-8304
Other Positions
TitleActive Staff Privileges
InstitutionBoston Medical Center
DepartmentMedicine

 Research Expertise & Professional Interests
Expertise includes: Arterial Thrombosis; Venous Thrombosis; Atrial Fibrillation; Safety and Effectiveness of Antithrombotic Therapy.

 Self-Described Keywords
  • Antithrombotic Therapy
  • Atrial Fibrillation
  • Intracranial Hemorrhage
  • Stroke
  • Thrombosis
 Publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Pandey A, Kim S, Moore C, Thomas L, Gersh B, Allen LA, Kowey PR, Mahaffey KW, Hylek E, Peterson ED, Piccini JP, Fonarow GC. Predictors and Prognostic Implications of Incident Heart Failure in Patients With Prevalent Atrial Fibrillation. JACC Heart Fail. 2017 Jan; 5(1):44-52. PMID: 28034376.
    View in: PubMed
  2. Pandey A, Kim S, Moore C, Thomas L, Gersh B, Allen LA, Kowey PR, Mahaffey KW, Hylek E, Peterson ED, Piccini JP, Fonarow GC. Predictors and Prognostic Implications of Incident Heart Failure in Patients With Prevalent Atrial Fibrillation. JACC Heart Fail. 2016 Nov 30. PMID: 28017349.
    View in: PubMed
  3. Kapoor A, Ellis A, Shaffer N, Gurwitz J, Chandramohan A, Saulino J, Ishak A, Okubanjo T, Michota F, Hylek E, Trikalinos TA. Comparative effectiveness of venous thromboembolism prophylaxis options for the patient undergoing total hip and knee replacement: a network meta-analysis. J Thromb Haemost. 2016 Nov 07. PMID: 28102615.
    View in: PubMed
  4. Ko D, Rahman F, Martins MA, Hylek EM, Ellinor PT, Schnabel RB, Benjamin EJ, Christophersen IE. Atrial fibrillation in women: treatment. Nat Rev Cardiol. 2017 Feb; 14(2):113-124. PMID: 27786235.
    View in: PubMed
  5. Bahit MC, Lopes RD, Wojdyla DM, Held C, Hanna M, Vinereanu D, Hylek EM, Verheugt F, Goto S, Alexander JH, Wallentin L, Granger CB. Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation. Heart. 2016 Oct 24. PMID: 27798052.
    View in: PubMed
  6. Pokorney SD, Shrader P, Thomas L, Fonarow GC, Kowey PR, Singer DE, Ansell J, Gersh BJ, Mahaffey KW, Hylek EM, Go AS, Piccini JP, Peterson ED. Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administration's Approach for Its Product Labeling. Circulation. 2016 Oct 11; 134(15):1122-1124. PMID: 27753615.
    View in: PubMed
  7. Hylek EM, Ko D. Atrial Fibrillation and Fall Risk: What Are the Treatment Implications? J Am Coll Cardiol. 2016 Sep 13; 68(11):1179-80. PMID: 27609679.
    View in: PubMed
  8. Pokorney SD, Simon DN, Thomas L, Gersh BJ, Hylek EM, Piccini JP, Peterson ED. Stability of International Normalized Ratios in Patients Taking Long-term Warfarin Therapy. JAMA. 2016 Aug 9; 316(6):661-3. PMID: 27532922.
    View in: PubMed
  9. Hylek EM. Antithrombotic drug use: scientific breakthroughs, biological limits and physician behaviour. Heart. 2016 Dec 1; 102(23):1859-1860. PMID: 27504004.
    View in: PubMed
  10. Piccini JP, Simon DN, Steinberg BA, Thomas L, Allen LA, Fonarow GC, Gersh B, Hylek E, Kowey PR, Reiffel JA, Naccarelli GV, Chan PS, Spertus JA, Peterson ED. Differences in Clinical and Functional Outcomes of Atrial Fibrillation in Women and Men: Two-Year Results From the ORBIT-AF Registry. JAMA Cardiol. 2016 Jun 1; 1(3):282-91. PMID: 27438106.
    View in: PubMed
  11. Ruff CT, Ansell JE, Becker RC, Benjamin EJ, Deicicchi DJ, Mark Estes NA, Ezekowitz MD, Fanikos J, Fareed J, Garcia D, Giugliano RP, Goldhaber SZ, Granger C, Healey JS, Hull R, Hylek EM, Libby P, Lopes RD, Mahaffey KW, Mega J, Piazza G, Sasahara AA, Sorond FA, Spyropoulos AC, Walenga JM, Weitz JI. North American Thrombosis Forum, AF Action Initiative Consensus Document. Am J Med. 2016 May; 129(5 Suppl):S1-S29. PMID: 27126598.
    View in: PubMed
  12. Hijazi Z, Oldgren J, Lindbäck J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Held C, Hylek EM, Lopes RD, Siegbahn A, Yusuf S, Granger CB, Wallentin L. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet. 2016 Jun 4; 387(10035):2302-11. PMID: 27056738.
    View in: PubMed
  13. Albers GW, Bernstein RA, Brachmann J, Camm J, Easton JD, Fromm P, Goto S, Granger CB, Hohnloser SH, Hylek E, Jaffer AK, Krieger DW, Passman R, Pines JM, Reed SD, Rothwell PM, Kowey PR. Heart Rhythm Monitoring Strategies for Cryptogenic Stroke: 2015 Diagnostics and Monitoring Stroke Focus Group Report. J Am Heart Assoc. 2016 Mar 15; 5(3):e002944. PMID: 27068633.
    View in: PubMed
  14. Procter NE, Ball J, Ngo DT, Isenberg JS, Hylek EM, Chirkov YY, Stewart S, Horowitz JD. Gender and tachycardia: independent modulation of platelet reactivity in patients with atrial fibrillation. J Geriatr Cardiol. 2016 Mar; 13(3):202-8. PMID: 27103914.
    View in: PubMed
  15. Hijazi Z, Lindbäck J, Alexander JH, Hanna M, Held C, Hylek EM, Lopes RD, Oldgren J, Siegbahn A, Stewart RA, White HD, Granger CB, Wallentin L. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J. 2016 May 21; 37(20):1582-90. PMID: 26920728.
    View in: PubMed
  16. Gundlund A, Fosbøl EL, Kim S, Fonarow GC, Gersh BJ, Kowey PR, Hylek E, Mahaffey KW, Thomas L, Piccini JP, Peterson ED. Family history of atrial fibrillation is associated with earlier-onset and more symptomatic atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Am Heart J. 2016 May; 175:28-35. PMID: 27179721.
    View in: PubMed
  17. Hijazi Z, Aulin J, Andersson U, Alexander JH, Gersh B, Granger CB, Hanna M, Horowitz J, Hylek EM, Lopes RD, Siegbahn A, Wallentin L. Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation. Heart. 2016 Apr; 102(7):508-17. PMID: 26839066.
    View in: PubMed
  18. Aronis KN, Hylek EM. Who, when, and how to reverse non-vitamin K oral anticoagulants. J Thromb Thrombolysis. 2016 Feb; 41(2):253-72. PMID: 26627486.
    View in: PubMed
  19. De Caterina R, Andersson U, Alexander JH, Al-Khatib SM, Bahit MC, Goto S, Hanna M, Held C, Hohnloser S, Hylek EM, Lanas F, Lopes RD, López-Sendón J, Renda G, Horowitz J, Granger CB, Wallentin L. History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. Am Heart J. 2016 May; 175:175-83. PMID: 27179738.
    View in: PubMed
  20. Lopes RD, Rao M, Simon DN, Thomas L, Ansell J, Fonarow GC, Gersh BJ, Go AS, Hylek EM, Kowey P, Piccini JP, Singer DE, Chang P, Peterson ED, Mahaffey KW. Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. Am J Med. 2016 Jun; 129(6):592-599.e1. PMID: 26797080.
    View in: PubMed
  21. Levy JH, Weitz JI, Bernstein RA, Eikelboom J, Hylek E, Huisman MV, Reilly PA, Steiner T, Kamphuisen P, Kam CW, Pollack CV. Letter to the Editor: Managing Dabigatran-Related Bleeding. J Intensive Care Med. 2016 Jan; 31(1):70-1. PMID: 26663474.
    View in: PubMed
  22. Golwala H, Jackson LR, Simon DN, Piccini JP, Gersh B, Go AS, Hylek EM, Kowey PR, Mahaffey KW, Thomas L, Fonarow GC, Peterson ED, Thomas KL. Racial/ethnic differences in atrial fibrillation symptoms, treatment patterns, and outcomes: Insights from Outcomes Registry for Better Informed Treatment for Atrial Fibrillation Registry. Am Heart J. 2016 Apr; 174:29-36. PMID: 26995367.
    View in: PubMed
  23. Rao MP, Halvorsen S, Wojdyla D, Thomas L, Alexander JH, Hylek EM, Hanna M, Bahit MC, Lopes RD, De Caterina R, Erol C, Goto S, Lanas F, Lewis BS, Husted S, Gersh BJ, Wallentin L, Granger CB. Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. J Am Heart Assoc. 2015 Dec; 4(12). PMID: 26627878.
    View in: PubMed
  24. Witt DM, Clark NP, Martinez K, Schroeder A, Garcia D, Crowther MA, Ageno W, Dentali F, Ye X, Hylek E, Delate T. Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for intracranial hemorrhage. Thromb Res. 2015 Nov; 136(5):1040-4. PMID: 26454758.
    View in: PubMed
  25. Triller DM, Wymer S, Meek PD, Hylek EM, Ansell JE. Trends in Warfarin Monitoring Practices Among New York Medicare Beneficiaries, 2006-2011. J Community Health. 2015 Oct; 40(5):845-54. PMID: 26198584.
    View in: PubMed
  26. O'Brien EC, Simon DN, Thomas LE, Hylek EM, Gersh BJ, Ansell JE, Kowey PR, Mahaffey KW, Chang P, Fonarow GC, Pencina MJ, Piccini JP, Peterson ED. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J. 2015 Dec 7; 36(46):3258-64. PMID: 26424865.
    View in: PubMed
  27. Vinereanu D, Stevens SR, Alexander JH, Al-Khatib SM, Avezum A, Bahit MC, Granger CB, Lopes RD, Halvorsen S, Hanna M, Husted S, Hylek EM, Margulescu AD, Wallentin L, Atar D. Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial. Eur Heart J. 2015 Dec 7; 36(46):3268-75. PMID: 26371113.
    View in: PubMed
  28. Steinberg BA, Kim S, Thomas L, Fonarow GC, Gersh BJ, Holmqvist F, Hylek E, Kowey PR, Mahaffey KW, Naccarelli G, Reiffel JA, Chang P, Peterson ED, Piccini JP. Increased Heart Rate Is Associated With Higher Mortality in Patients With Atrial Fibrillation (AF): Results From the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF). J Am Heart Assoc. 2015 Sep; 4(9):e002031. PMID: 26370445.
    View in: PubMed
  29. Aronis KN, Thigpen JL, Tripodis Y, Dillon C, Forster K, Henault L, Quinn EK, Berger PB, Limdi NA, Hylek EM. Paroxysmal atrial fibrillation and the hazards of under-treatment. Int J Cardiol. 2016 Jan 1; 202:214-20. PMID: 26397414.
    View in: PubMed
  30. Wendelboe AM, McCumber M, Hylek EM, Buller H, Weitz JI, Raskob G. Global public awareness of venous thromboembolism. J Thromb Haemost. 2015 Aug; 13(8):1365-71. PMID: 26084415.
    View in: PubMed
  31. Andreotti F, Rocca B, Husted S, Ajjan RA, ten Berg J, Cattaneo M, Collet JP, De Caterina R, Fox KA, Halvorsen S, Huber K, Hylek EM, Lip GY, Montalescot G, Morais J, Patrono C, Verheugt FW, Wallentin L, Weiss TW, Storey RF. Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. Eur Heart J. 2015 Dec 7; 36(46):3238-49. PMID: 26163482.
    View in: PubMed
  32. Procter NE, Ball J, Ngo DT, Chirkov YY, Isenberg JS, Hylek EM, Stewart S, Horowitz JD. Platelet hyperaggregability in patients with atrial fibrillation. Evidence of a background proinflammatory milieu. Herz. 2016 Feb; 41(1):57-62. PMID: 26135468.
    View in: PubMed
  33. Allen LA, Fonarow GC, Simon DN, Thomas LE, Marzec LN, Pokorney SD, Gersh BJ, Go AS, Hylek EM, Kowey PR, Mahaffey KW, Chang P, Peterson ED, Piccini JP. Digoxin Use and Subsequent Outcomes Among Patients in a Contemporary Atrial Fibrillation Cohort. J Am Coll Cardiol. 2015 Jun 30; 65(25):2691-8. PMID: 26112191.
    View in: PubMed
  34. Lane DA, Aguinaga L, Blomström-Lundqvist C, Boriani G, Dan GA, Hills MT, Hylek EM, LaHaye SA, Lip GY, Lobban T, Mandrola J, McCabe PJ, Pedersen SS, Pisters R, Stewart S, Wood K, Potpara TS, Gorenek B, Conti JB, Keegan R, Power S, Hendriks J, Ritter P, Calkins H, Violi F, Hurwitz J. Cardiac tachyarrhythmias and patient values and preferences for their management: the European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). Europace. 2015 Dec; 17(12):1747-69. PMID: 26108807.
    View in: PubMed
  35. Pollack CV, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen PW, Kreuzer J, Levy JH, Sellke FW, Stangier J, Steiner T, Wang B, Kam CW, Weitz JI. Idarucizumab for Dabigatran Reversal. N Engl J Med. 2015 Aug 6; 373(6):511-20. PMID: 26095746.
    View in: PubMed
  36. Freeman JV, Simon DN, Go AS, Spertus J, Fonarow GC, Gersh BJ, Hylek EM, Kowey PR, Mahaffey KW, Thomas LE, Chang P, Peterson ED, Piccini JP. Association Between Atrial Fibrillation Symptoms, Quality of Life, and Patient Outcomes: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Circ Cardiovasc Qual Outcomes. 2015 Jul; 8(4):393-402. PMID: 26058720.
    View in: PubMed
  37. Pollack CV, Reilly PA, Bernstein R, Dubiel R, Eikelboom J, Glund S, Huisman MV, Hylek E, Kam CW, Kamphuisen PW, Kreuzer J, Levy JH, Sellke F, Stangier J, Steiner T, Wang B, Weitz JI. Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thromb Haemost. 2015 Jul; 114(1):198-205. PMID: 26020620.
    View in: PubMed
  38. Kim EJ, Ozonoff A, Hylek EM, Berlowitz DR, Ash AS, Miller DR, Zhao S, Reisman JI, Jasuja GK, Rose AJ. Predicting outcomes among patients with atrial fibrillation and heart failure receiving anticoagulation with warfarin. Thromb Haemost. 2015 Jul; 114(1):70-7. PMID: 25948532.
    View in: PubMed
  39. Sico JJ, Chang CC, So-Armah K, Justice AC, Hylek E, Skanderson M, McGinnis K, Kuller LH, Kraemer KL, Rimland D, Bidwell Goetz M, Butt AA, Rodriguez-Barradas MC, Gibert C, Leaf D, Brown ST, Samet J, Kazis L, Bryant K, Freiberg MS. HIV status and the risk of ischemic stroke among men. Neurology. 2015 May 12; 84(19):1933-40. PMID: 25862803.
    View in: PubMed
  40. Pokorney SD, Simon DN, Thomas L, Fonarow GC, Kowey PR, Chang P, Singer DE, Ansell J, Blanco RG, Gersh B, Mahaffey KW, Hylek EM, Go AS, Piccini JP, Peterson ED. Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry. Am Heart J. 2015 Jul; 170(1):141-8, 148.e1. PMID: 26093875.
    View in: PubMed
  41. Holmqvist F, Guan N, Zhu Z, Kowey PR, Allen LA, Fonarow GC, Hylek EM, Mahaffey KW, Freeman JV, Chang P, Holmes DN, Peterson ED, Piccini JP, Gersh BJ. Impact of obstructive sleep apnea and continuous positive airway pressure therapy on outcomes in patients with atrial fibrillation-Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Am Heart J. 2015 May; 169(5):647-654.e2. PMID: 25965712.
    View in: PubMed
  42. Ko D, Hylek EM. Left atrial appendage closure for stroke prevention in atrial fibrillation: response to an unmet need with an unclear direction. Circ Arrhythm Electrophysiol. 2015 Feb; 8(1):8-10. PMID: 25691551.
    View in: PubMed
  43. Thigpen JL, Dillon C, Forster KB, Henault L, Quinn EK, Tripodis Y, Berger PB, Hylek EM, Limdi NA. Validity of international classification of disease codes to identify ischemic stroke and intracranial hemorrhage among individuals with associated diagnosis of atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2015 Jan; 8(1):8-14. PMID: 25587093.
    View in: PubMed
  44. Ko D, Magnani JW, Hylek EM. Biomarkers in lone atrial fibrillation - an additional 'fine tuning' of risk? Curr Pharm Des. 2015; 21(5):646-58. PMID: 25175091.
    View in: PubMed
  45. Held C, Hylek EM, Alexander JH, Hanna M, Lopes RD, Wojdyla DM, Thomas L, Al-Khalidi H, Alings M, Xavier D, Ansell J, Goto S, Ruzyllo W, Rosenqvist M, Verheugt FW, Zhu J, Granger CB, Wallentin L. Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. Eur Heart J. 2015 May 21; 36(20):1264-72. PMID: 25499871.
    View in: PubMed
  46. Hijazi Z, Siegbahn A, Andersson U, Lindahl B, Granger CB, Alexander JH, Atar D, Gersh BJ, Hanna M, Harjola VP, Horowitz J, Husted S, Hylek EM, Lopes RD, McMurray JJ, Wallentin L. Comparison of cardiac troponins I and T measured with high-sensitivity methods for evaluation of prognosis in atrial fibrillation: an ARISTOTLE substudy. Clin Chem. 2015 Feb; 61(2):368-78. PMID: 25451868.
    View in: PubMed
  47. Raskob GE, Angchaisuksiri P, Blanco AN, Buller H, Gallus A, Hunt BJ, Hylek EM, Kakkar A, Konstantinides SV, McCumber M, Ozaki Y, Wendelboe A, Weitz JI. Thrombosis: a major contributor to global disease burden. Arterioscler Thromb Vasc Biol. 2014 Nov; 34(11):2363-71. PMID: 25304324.
    View in: PubMed
  48. Procter NE, Ball J, Liu S, Hurst N, Nooney VB, Goh V, Stafford I, Heresztyn T, Carrington M, Ngo DT, Hylek EM, Isenberg JS, Chirkov YY, Stewart S, Horowitz JD. Impaired platelet nitric oxide response in patients with new onset atrial fibrillation. Int J Cardiol. 2015 Jan 20; 179:160-5. PMID: 25464437.
    View in: PubMed
  49. Garcia D, Alexander JH, Wallentin L, Wojdyla DM, Thomas L, Hanna M, Al-Khatib SM, Dorian P, Ansell J, Commerford P, Flaker G, Lanas F, Vinereanu D, Xavier D, Hylek EM, Held C, Verheugt FW, Granger CB, Lopes RD. Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures. Blood. 2014 Dec 11; 124(25):3692-8. PMID: 25320240.
    View in: PubMed
  50. Flaker G, Lopes RD, Hylek E, Wojdyla DM, Thomas L, Al-Khatib SM, Sullivan RM, Hohnloser SH, Garcia D, Hanna M, Amerena J, Harjola VP, Dorian P, Avezum A, Keltai M, Wallentin L, Granger CB. Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial. J Am Coll Cardiol. 2014 Oct 14; 64(15):1541-50. PMID: 25301455.
    View in: PubMed
  51. Raskob GE, Angchaisuksiri P, Blanco AN, Büller H, Gallus A, Hunt BJ, Hylek EM, Kakkar TL, Konstantinides SV, McCumber M, Ozaki Y, Wendelboe A, Weitz JI. Thrombosis: a major contributor to global disease burden. Semin Thromb Hemost. 2014 Oct; 40(7):724-35. PMID: 25302681.
    View in: PubMed
  52. Wallentin L, Hijazi Z, Andersson U, Alexander JH, De Caterina R, Hanna M, Horowitz JD, Hylek EM, Lopes RD, Asberg S, Granger CB, Siegbahn A. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation. 2014 Nov 18; 130(21):1847-58. PMID: 25294786.
    View in: PubMed
  53. Granger CB, Lopes RD, Hanna M, Ansell J, Hylek EM, Alexander JH, Thomas L, Wang J, Bahit MC, Verheugt F, Lawrence J, Xavier D, Wallentin L. Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Am Heart J. 2015 Jan; 169(1):25-30. PMID: 25497244.
    View in: PubMed
  54. Kwaan HC, McMahon BJ, Hylek EM. Age-related changes in thrombosis and hemostasis. Semin Thromb Hemost. 2014 Sep; 40(6):619-20. PMID: 25259875.
    View in: PubMed
  55. Ko D, Hylek EM. Anticoagulation in the older adult: optimizing benefit and reducing risk. Semin Thromb Hemost. 2014 Sep; 40(6):688-94. PMID: 25184500.
    View in: PubMed
  56. Christersson C, Wallentin L, Andersson U, Alexander JH, Ansell J, De Caterina R, Gersh BJ, Granger CB, Hanna M, Horowitz JD, Huber K, Husted S, Hylek EM, Lopes RD, Siegbahn A. D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation--observations from the ARISTOTLE trial. J Thromb Haemost. 2014 Sep; 12(9):1401-12. PMID: 24942912.
    View in: PubMed
  57. Efird LM, Mishkin DS, Berlowitz DR, Ash AS, Hylek EM, Ozonoff A, Reisman JI, Zhao S, Jasuja GK, Rose AJ. Stratifying the risks of oral anticoagulation in patients with liver disease. Circ Cardiovasc Qual Outcomes. 2014 May; 7(3):461-7. PMID: 24823958.
    View in: PubMed
  58. Lip GY, Camm AJ, Hylek EM, Halperin JL, Weitz JI. Non-vitamin K antagonist oral anticoagulants: an appeal for consensus on terminology. Chest. 2014 May; 145(5):1177-8. PMID: 24798856.
    View in: PubMed
  59. Hess PL, Mirro MJ, Diener HC, Eikelboom JW, Al-Khatib SM, Hylek EM, Bosworth HB, Gersh BJ, Singer DE, Flaker G, Mega JL, Peterson ED, Rumsfeld JS, Steinberg BA, Kakkar AK, Califf RM, Granger CB. Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012. Am Heart J. 2014 Sep; 168(3):239-247.e1. PMID: 25173533.
    View in: PubMed
  60. Steinberg BA, Blanco RG, Ollis D, Kim S, Holmes DN, Kowey PR, Fonarow GC, Ansell J, Gersh B, Go AS, Hylek E, Mahaffey KW, Thomas L, Chang P, Peterson ED, Piccini JP. Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II: rationale and design of the ORBIT-AF II registry. Am Heart J. 2014 Aug; 168(2):160-7. PMID: 25066554.
    View in: PubMed
  61. Steinhubl SR, Eikelboom JW, Hylek EM, Dauerman HL, Smyth SS, Becker RC. Antiplatelet therapy in prevention of cardio- and venous thromboembolic events. J Thromb Thrombolysis. 2014 Apr; 37(3):362-71. PMID: 24221804.
    View in: PubMed
  62. Steinberg BA, Kim S, Thomas L, Fonarow GC, Hylek E, Ansell J, Go AS, Chang P, Kowey P, Gersh BJ, Mahaffey KW, Singer DE, Piccini JP, Peterson ED. Lack of concordance between empirical scores and physician assessments of stroke and bleeding risk in atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Circulation. 2014 May 20; 129(20):2005-12. PMID: 24682387.
    View in: PubMed
  63. Hylek EM, Held C, Alexander JH, Lopes RD, De Caterina R, Wojdyla DM, Huber K, Jansky P, Steg PG, Hanna M, Thomas L, Wallentin L, Granger CB. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. J Am Coll Cardiol. 2014 May 27; 63(20):2141-7. PMID: 24657685.
    View in: PubMed
  64. Rao SR, Reisman JI, Kressin NR, Berlowitz DR, Ash AS, Ozonoff A, Miller DR, Hylek EM, Zhao S, Rose AJ. Explaining racial disparities in anticoagulation control: results from a study of patients at the Veterans Administration. Am J Med Qual. 2015 May; 30(3):214-22. PMID: 24642366.
    View in: PubMed
  65. Clark NP, Delate T, Riggs CS, Witt DM, Hylek EM, Garcia DA, Ageno W, Dentali F, Crowther MA. Warfarin interactions with antibiotics in the ambulatory care setting. JAMA Intern Med. 2014 Mar; 174(3):409-16. PMID: 24445404.
    View in: PubMed
  66. Hylek EM, Ko D, Cove CL. Gaps in translation from trials to practice: non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in atrial fibrillation. Thromb Haemost. 2014 May 5; 111(5):783-8. PMID: 24573511.
    View in: PubMed
  67. Halvorsen S, Atar D, Yang H, De Caterina R, Erol C, Garcia D, Granger CB, Hanna M, Held C, Husted S, Hylek EM, Jansky P, Lopes RD, Ruzyllo W, Thomas L, Wallentin L. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J. 2014 Jul 21; 35(28):1864-72. PMID: 24561548.
    View in: PubMed
  68. Paradise HT, Berlowitz DR, Ozonoff A, Miller DR, Hylek EM, Ash AS, Jasuja GK, Zhao S, Reisman JI, Rose AJ. Outcomes of anticoagulation therapy in patients with mental health conditions. J Gen Intern Med. 2014 Jun; 29(6):855-61. PMID: 24549520.
    View in: PubMed
  69. Steinberg BA, Kim S, Fonarow GC, Thomas L, Ansell J, Kowey PR, Mahaffey KW, Gersh BJ, Hylek E, Naccarelli G, Go AS, Reiffel J, Chang P, Peterson ED, Piccini JP. Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Am Heart J. 2014 May; 167(5):735-42.e2. PMID: 24766985.
    View in: PubMed
  70. Hylek EM. The gender gap in academic leadership. Rev Clin Esp (Barc). 2014 Mar; 214(2):83-4. PMID: 24513082.
    View in: PubMed
  71. Dlott JS, George RA, Huang X, Odeh M, Kaufman HW, Ansell J, Hylek EM. National assessment of warfarin anticoagulation therapy for stroke prevention in atrial fibrillation. Circulation. 2014 Apr 1; 129(13):1407-14. PMID: 24493817.
    View in: PubMed
  72. Cancino RS, Hylek EM, Reisman JI, Rose AJ. Comparing patient-level and site-level anticoagulation control as predictors of adverse events. Thromb Res. 2014 Apr; 133(4):652-6. PMID: 24502961.
    View in: PubMed
  73. Wallentin L, Lopes RD, Hanna M, Thomas L, Hellkamp A, Nepal S, Hylek EM, Al-Khatib SM, Alexander JH, Alings M, Amerena J, Ansell J, Aylward P, Bartunek J, Commerford P, De Caterina R, Erol C, Harjola VP, Held C, Horowitz J, Huber K, Husted S, Keltai M, Lanas F, Lisheng L, McMurray JJ, Oh BH, Rosenqvist M, Ruzyllo W, Steg PG, Vinereanu D, Xavier D, Granger CB. Response to letter regarding article, "Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation". Circulation. 2014 Jan 14; 129(2):e21-2. PMID: 24421367.
    View in: PubMed
  74. O'Brien EC, Holmes DN, Ansell JE, Allen LA, Hylek E, Kowey PR, Gersh BJ, Fonarow GC, Koller CR, Ezekowitz MD, Mahaffey KW, Chang P, Peterson ED, Piccini JP, Singer DE. Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Am Heart J. 2014 Apr; 167(4):601-609.e1. PMID: 24655711.
    View in: PubMed
  75. Cove CL, Albert CM, Andreotti F, Badimon L, Van Gelder IC, Hylek EM. Female sex as an independent risk factor for stroke in atrial fibrillation: possible mechanisms. Thromb Haemost. 2014 Mar 3; 111(3):385-91. PMID: 24305974.
    View in: PubMed
  76. Steinberg BA, Holmes DN, Piccini JP, Ansell J, Chang P, Fonarow GC, Gersh B, Mahaffey KW, Kowey PR, Ezekowitz MD, Singer DE, Thomas L, Peterson ED, Hylek EM. Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation. J Am Heart Assoc. 2013; 2(6):e000535. PMID: 24275632.
    View in: PubMed
  77. Hijazi Z, Siegbahn A, Andersson U, Granger CB, Alexander JH, Atar D, Gersh BJ, Mohan P, Harjola VP, Horowitz J, Husted S, Hylek EM, Lopes RD, McMurray JJ, Wallentin L. High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation. 2014 Feb 11; 129(6):625-34. PMID: 24226808.
    View in: PubMed
  78. Cove CL, Hylek EM. An updated review of target-specific oral anticoagulants used in stroke prevention in atrial fibrillation, venous thromboembolic disease, and acute coronary syndromes. J Am Heart Assoc. 2013 Oct; 2(5):e000136. PMID: 24152980.
    View in: PubMed
  79. Witt DM, Delate T, Hylek EM, Clark NP, Crowther MA, Dentali F, Ageno W, Martinez KD, Garcia DA. Effect of warfarin on intracranial hemorrhage incidence and fatal outcomes. Thromb Res. 2013; 132(6):770-5. PMID: 24521790.
    View in: PubMed
  80. Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Alexander JH, Atar D, Gersh BJ, Hanna M, Harjola VP, Horowitz JD, Husted S, Hylek EM, Lopes RD, McMurray JJ, Granger CB. High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin. J Am Coll Cardiol. 2014 Jan 7-14; 63(1):52-61. PMID: 24055845.
    View in: PubMed
  81. Hylek EM. Dabigatran and mechanical heart valves--not as easy as we hoped. N Engl J Med. 2013 Sep 26; 369(13):1264-6. PMID: 23991659.
    View in: PubMed
  82. Garcia DA, Wallentin L, Lopes RD, Thomas L, Alexander JH, Hylek EM, Ansell J, Hanna M, Lanas F, Flaker G, Commerford P, Xavier D, Vinereanu D, Yang H, Granger CB. Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. Am Heart J. 2013 Sep; 166(3):549-58. PMID: 24016506.
    View in: PubMed
  83. Magnani JW, Hylek EM, Apovian CM. Obesity begets atrial fibrillation: a contemporary summary. Circulation. 2013 Jul 23; 128(4):401-5. PMID: 23877062.
    View in: PubMed
  84. Steinberg BA, Kim S, Piccini JP, Fonarow GC, Lopes RD, Thomas L, Ezekowitz MD, Ansell J, Kowey P, Singer DE, Gersh B, Mahaffey KW, Hylek E, Go AS, Chang P, Peterson ED. Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. Circulation. 2013 Aug 13; 128(7):721-8. PMID: 23861512.
    View in: PubMed
  85. Lopes RD, Becker RC, Newby LK, Peterson ED, Hylek EM, Giugliano R, Granger CB, Mahaffey KW, Carvalho AC, Berwanger O, Giraldez RR, Feitosa-Filho GS, Barbosa MM, da Consolacao V Moreira M, Kalil RA, Freitas M, de Campos Guerra JC, Barros MV, da Rocha Rodrigues T, Lopes AC, Garcia DA. Highlights from the fifth international symposium of thrombosis and anticoagulation (ISTA V), October 18-19, 2012, Belo Horizonte, Minas Gerais, Brazil. J Thromb Thrombolysis. 2013 Jul; 36(1):115-30. PMID: 23494487.
    View in: PubMed
  86. Witt DM, Delate T, Clark NP, Garcia DA, Hylek EM, Ageno W, Dentali F, Crowther MA. Nonadherence with INR monitoring and anticoagulant complications. Thromb Res. 2013 Aug; 132(2):e124-30. PMID: 23800635.
    View in: PubMed
  87. Cullen MW, Kim S, Piccini JP, Ansell JE, Fonarow GC, Hylek EM, Singer DE, Mahaffey KW, Kowey PR, Thomas L, Go AS, Lopes RD, Chang P, Peterson ED, Gersh BJ. Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Circ Cardiovasc Qual Outcomes. 2013 Jul; 6(4):461-9. PMID: 23759473.
    View in: PubMed
  88. Wallentin L, Lopes RD, Hanna M, Thomas L, Hellkamp A, Nepal S, Hylek EM, Al-Khatib SM, Alexander JH, Alings M, Amerena J, Ansell J, Aylward P, Bartunek J, Commerford P, De Caterina R, Erol C, Harjola VP, Held C, Horowitz JD, Huber K, Husted S, Keltai M, Lanas F, Lisheng L, McMurray JJ, Oh BH, Rosenqvist M, Ruzyllo W, Steg PG, Vinereanu D, Xavier D, Granger CB. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation. 2013 Jun 4; 127(22):2166-76. PMID: 23640971.
    View in: PubMed
  89. Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Christersson C, Ezekowitz J, Gersh BJ, Hanna M, Hohnloser S, Horowitz J, Huber K, Hylek EM, Lopes RD, McMurray JJ, Granger CB. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). J Am Coll Cardiol. 2013 Jun 4; 61(22):2274-84. PMID: 23563134.
    View in: PubMed
  90. Guyatt G, Eikelboom J, Crowther M, Akl E, Francis C, Garcia D, Gould M, Hylek E, Kahn S, Kunz R, Quinlan D, Vandvik P, Hirsh J. A response to--there's madness in their methods. J Thromb Haemost. 2013 Apr; 11(4):785-6. PMID: 23406024.
    View in: PubMed
  91. Hylek EM. Vitamin K antagonists and time in the therapeutic range: implications, challenges, and strategies for improvement. J Thromb Thrombolysis. 2013 Apr; 35(3):333-5. PMID: 23456572.
    View in: PubMed
  92. Kapoor A, Chew P, Silliman RA, Hylek EM, Katz JN, Cabral H, Berlowitz D. Venous thromboembolism after joint replacement in older male veterans with comorbidity. J Am Geriatr Soc. 2013 Apr; 61(4):590-601. PMID: 23581913.
    View in: PubMed
  93. Rose AJ, Miller DR, Ozonoff A, Berlowitz DR, Ash AS, Zhao S, Reisman JI, Hylek EM. Gaps in monitoring during oral anticoagulation: insights into care transitions, monitoring barriers, and medication nonadherence. Chest. 2013 Mar; 143(3):751-7. PMID: 23187457.
    View in: PubMed
  94. Hylek EM. Anticoagulation therapy for atrial fibrillation. Semin Thromb Hemost. 2013 Mar; 39(2):147-52. PMID: 23397554.
    View in: PubMed
  95. Hanchate AD, Schwamm LH, Huang W, Hylek EM. Comparison of ischemic stroke outcomes and patient and hospital characteristics by race/ethnicity and socioeconomic status. Stroke. 2013 Feb; 44(2):469-76. PMID: 23306327.
    View in: PubMed
  96. Jasuja GK, Reisman JI, Miller DR, Berlowitz DR, Hylek EM, Ash AS, Ozonoff A, Zhao S, Rose AJ. Identifying major hemorrhage with automated data: results of the Veterans Affairs study to improve anticoagulation (VARIA). Thromb Res. 2013 Jan; 131(1):31-6. PMID: 23158402.
    View in: PubMed
  97. Witt DM, Delate T, Garcia DA, Clark NP, Hylek EM, Ageno W, Dentali F, Crowther MA. Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding. Arch Intern Med. 2012 Oct 22; 172(19):1484-91. PMID: 22987143.
    View in: PubMed
  98. Lopes RD, Al-Khatib SM, Wallentin L, Yang H, Ansell J, Bahit MC, De Caterina R, Dorian P, Easton JD, Erol C, Ezekowitz JA, Gersh BJ, Granger CB, Hohnloser SH, Horowitz J, Hylek EM, McMurray JJ, Mohan P, Vinereanu D, Alexander JH. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. Lancet. 2012 Nov 17; 380(9855):1749-58. PMID: 23036896.
    View in: PubMed
  99. Hlatky MA, Douglas PS, Cook NL, Wells B, Benjamin EJ, Dickersin K, Goff DC, Hirsch AT, Hylek EM, Peterson ED, Roger VL, Selby JV, Udelson JE, Lauer MS. Future directions for cardiovascular disease comparative effectiveness research: report of a workshop sponsored by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol. 2012 Aug 14; 60(7):569-80. PMID: 22796257.
    View in: PubMed
  100. Lopes RD, Becker RC, Newby LK, Peterson ED, Hylek EM, Granger CB, Crowther M, Wang T, Carvalho AC, Berwanger O, Giraldez RR, Feitosa GS, Ribeiro JP, Darze E, Kalil RA, Andrande M, Boas FV, Andrade J, Rocha AT, Harrington RA, Lopes AC, Garcia DA. Highlights from the IV International Symposium of Thrombosis and Anticoagulation (ISTA), October 20-21, 2011, Salvador, Bahia, Brazil. J Thromb Thrombolysis. 2012 Jul; 34(1):143-63. PMID: 22427055.
    View in: PubMed
  101. Rose AJ, Berlowitz DR, Miller DR, Hylek EM, Ozonoff A, Zhao S, Reisman JI, Ash AS. INR targets and site-level anticoagulation control: results from the Veterans AffaiRs Study to Improve Anticoagulation (VARIA). J Thromb Haemost. 2012 Apr; 10(4):590-5. PMID: 22288563.
    View in: PubMed
  102. Rose AJ, Petrakis BA, Callahan P, Mambourg S, Patel D, Hylek EM, Bokhour BG. Organizational characteristics of high- and low-performing anticoagulation clinics in the Veterans Health Administration. Health Serv Res. 2012 Aug; 47(4):1541-60. PMID: 22299722.
    View in: PubMed
  103. You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, Hylek EM, Schulman S, Go AS, Hughes M, Spencer FA, Manning WJ, Halperin JL, Lip GY. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb; 141(2 Suppl):e531S-75S. PMID: 22315271.
    View in: PubMed
  104. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb; 141(2 Suppl):e44S-88S. PMID: 22315269.
    View in: PubMed
  105. Lip GY, Andreotti F, Fauchier L, Huber K, Hylek E, Knight E, Lane D, Levi M, Marín F, Palareti G, Kirchhof P. Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost. 2011 Dec; 106(6):997-1011. PMID: 22048796.
    View in: PubMed
  106. Kirchhof P, Lip GY, Van Gelder IC, Bax J, Hylek E, Kääb S, Schotten U, Wegscheider K, Boriani G, Ezekowitz M, Diener H, Heidbuchel H, Lane D, Mont L, Willems S, Dorian P, Vardas P, Breithardt G, Camm AJ. Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and therapeutic options. Executive summary of the report from the 3rd AFNET/EHRA consensus conference. Thromb Haemost. 2011 Dec; 106(6):1012-9. PMID: 22048744.
    View in: PubMed
  107. Piccini JP, Fraulo ES, Ansell JE, Fonarow GC, Gersh BJ, Go AS, Hylek EM, Kowey PR, Mahaffey KW, Thomas LE, Kong MH, Lopes RD, Mills RM, Peterson ED. Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF. Am Heart J. 2011 Oct; 162(4):606-612.e1. PMID: 21982650.
    View in: PubMed
  108. Lopes RD, Horowitz JD, Garcia DA, Crowther MA, Hylek EM. Warfarin and acetaminophen interaction: a summary of the evidence and biologic plausibility. Blood. 2011 Dec 8; 118(24):6269-73. PMID: 21911832.
    View in: PubMed
  109. De Caterina R, Hylek EM. Stroke prevention in atrial fibrillation: current status and near-future directions. Am J Med. 2011 Sep; 124(9):793-9. PMID: 21745652.
    View in: PubMed
  110. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 Sep 15; 365(11):981-92. PMID: 21870978.
    View in: PubMed
  111. Lopes RD, Becker RC, Alexander JH, Armstrong PW, Califf RM, Chan MY, Crowther M, Granger CB, Harrington RA, Hylek EM, James SK, Jolicoeur EM, Mahaffey KW, Newby LK, Peterson ED, Pieper KS, Van de Werf F, Wallentin L, White HD, Carvalho AC, Giraldez RR, Guimaraes HP, Nader HB, Kalil RA, Bizzachi JM, Lopes AC, Garcia DA. Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14-16, 2010, São Paulo, Brazil. J Thromb Thrombolysis. 2011 Aug; 32(2):242-66. PMID: 21547405.
    View in: PubMed
  112. Dentali F, Marchesi C, Pierfranceschi MG, Crowther M, Garcia D, Hylek E, Witt DM, Clark NP, Squizzato A, Imberti D, Ageno W. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. Thromb Haemost. 2011 Sep; 106(3):429-38. PMID: 21800002.
    View in: PubMed
  113. Kirchhof P, Lip GY, Van Gelder IC, Bax J, Hylek E, Kaab S, Schotten U, Wegscheider K, Boriani G, Brandes A, Ezekowitz M, Diener H, Haegeli L, Heidbuchel H, Lane D, Mont L, Willems S, Dorian P, Aunes-Jansson M, Blomstrom-Lundqvist C, Borentain M, Breitenstein S, Brueckmann M, Cater N, Clemens A, Dobrev D, Dubner S, Edvardsson NG, Friberg L, Goette A, Gulizia M, Hatala R, Horwood J, Szumowski L, Kappenberger L, Kautzner J, Leute A, Lobban T, Meyer R, Millerhagen J, Morgan J, Muenzel F, Nabauer M, Baertels C, Oeff M, Paar D, Polifka J, Ravens U, Rosin L, Stegink W, Steinbeck G, Vardas P, Vincent A, Walter M, Breithardt G, Camm AJ. Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options--a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. Europace. 2012 Jan; 14(1):8-27. PMID: 21791573.
    View in: PubMed
  114. Rose AJ, Berlowitz DR, Ash AS, Ozonoff A, Hylek EM, Goldhaber-Fiebert JD. The business case for quality improvement: oral anticoagulation for atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2011 Jul; 4(4):416-24. PMID: 21712521.
    View in: PubMed
  115. Estes NA, Sacco RL, Al-Khatib SM, Ellinor PT, Bezanson J, Alonso A, Antzelevitch C, Brockman RG, Chen PS, Chugh SS, Curtis AB, DiMarco JP, Ellenbogen KA, Epstein AE, Ezekowitz MD, Fayad P, Gage BF, Go AS, Hlatky MA, Hylek EM, Jerosch-Herold M, Konstam MA, Lee R, Packer DL, Po SS, Prystowsky EN, Redline S, Rosenberg Y, Van Wagoner DR, Wood KA, Yue L, Benjamin EJ. American Heart Association atrial fibrillation research summit: a conference report from the American Heart Association. Circulation. 2011 Jul 19; 124(3):363-72. PMID: 21709057.
    View in: PubMed
  116. Dentali F, Gianni M, Squizzato A, Ageno W, Castiglioni L, Maroni L, Hylek EM, Grandi AM, Cazzani E, Venco A, Guasti L. Use of statins and recurrence of atrial fibrillation after catheter ablation or electrical cardioversion. A systematic review and meta-analysis. Thromb Haemost. 2011 Aug; 106(2):363-70. PMID: 21614408.
    View in: PubMed
  117. Lip GY, Andreotti F, Fauchier L, Huber K, Hylek E, Knight E, Lane DA, Levi M, Marin F, Palareti G, Kirchhof P. Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. Europace. 2011 May; 13(5):723-46. PMID: 21515596.
    View in: PubMed
  118. Rose AJ, Hylek EM, Berlowitz DR, Ash AS, Reisman JI, Ozonoff A. Prompt repeat testing after out-of-range INR values: a quality indicator for anticoagulation care. Circ Cardiovasc Qual Outcomes. 2011 May; 4(3):276-82. PMID: 21505156.
    View in: PubMed
  119. Rose AJ, Hylek EM, Ozonoff A, Ash AS, Reisman JI, Callahan PP, Gordon MM, Berlowitz DR. Relevance of current guidelines for organizing an anticoagulation clinic. Am J Manag Care. 2011 Apr; 17(4):284-9. PMID: 21615198.
    View in: PubMed
  120. Dentali F, Donadini MP, Clark N, Crowther MA, Garcia D, Hylek E, Witt DM, Ageno W. Brand name versus generic warfarin: a systematic review of the literature. Pharmacotherapy. 2011 Apr; 31(4):386-93. PMID: 21449627.
    View in: PubMed
  121. Cabral KP, Ansell J, Hylek EM. Future directions of stroke prevention in atrial fibrillation: the potential impact of novel anticoagulants and stroke risk stratification. J Thromb Haemost. 2011 Mar; 9(3):441-9. PMID: 21176102.
    View in: PubMed
  122. Rose AJ, Ozonoff A, Berlowitz DR, Ash AS, Reisman JI, Hylek EM. Reexamining the recommended follow-up interval after obtaining an in-range international normalized ratio value: results from the Veterans Affairs study to improve anticoagulation. Chest. 2011 Aug; 140(2):359-65. PMID: 21310837.
    View in: PubMed
  123. Hylek EM. Therapeutic potential of oral factor Xa inhibitors. N Engl J Med. 2010 Dec 23; 363(26):2559-61. PMID: 21175319.
    View in: PubMed
  124. Rose AJ, Hylek EM, Ozonoff A, Ash AS, Reisman JI, Berlowitz DR. Risk-adjusted percent time in therapeutic range as a quality indicator for outpatient oral anticoagulation: results of the Veterans Affairs Study to Improve Anticoagulation (VARIA). Circ Cardiovasc Qual Outcomes. 2011 Jan 1; 4(1):22-9. PMID: 21098779.
    View in: PubMed
  125. Rose AJ, Hylek EM, Ozonoff A, Ash AS, Reisman JI, Berlowitz DR. Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA). J Thromb Haemost. 2010 Oct; 8(10):2182-91. PMID: 20653840.
    View in: PubMed
  126. Garcia DA, Lopes RD, Hylek EM. New-onset atrial fibrillation and warfarin initiation: high risk periods and implications for new antithrombotic drugs. Thromb Haemost. 2010 Dec; 104(6):1099-105. PMID: 20886196.
    View in: PubMed
  127. Rose AJ, Hylek EM. High blood pressure while taking antithrombotic medication is associated with an increased risk of developing intracranial haemorrhage. Evid Based Med. 2010 Dec; 15(6):189-90. PMID: 20797990.
    View in: PubMed
  128. Witt DM, Delate T, Clark NP, Martell C, Tran T, Crowther MA, Garcia DA, Ageno W, Hylek EM. Twelve-month outcomes and predictors of very stable INR control in prevalent warfarin users. J Thromb Haemost. 2010 Apr; 8(4):744-9. PMID: 20398186.
    View in: PubMed
  129. Cowan A, Hylek EM. Bleeding risk on warfarin among elderly patients with atrial fibrillation. J Am Coll Cardiol. 2010 Mar 2; 55(9):932; author reply 932-3. PMID: 20185052.
    View in: PubMed
  130. Lopes RD, Alexander JH, Al-Khatib SM, Ansell J, Diaz R, Easton JD, Gersh BJ, Granger CB, Hanna M, Horowitz J, Hylek EM, McMurray JJ, Verheugt FW, Wallentin L. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J. 2010 Mar; 159(3):331-9. PMID: 20211292.
    View in: PubMed
  131. Rose AJ, Ozonoff A, Henault LE, Hylek EM. Anticoagulation for valvular heart disease in community-based practice. Thromb Haemost. 2010 Feb; 103(2):329-37. PMID: 20024499.
    View in: PubMed
  132. Hylek EM. Antithrombotic prophylaxis in elderly patients with atrial fibrillation. Semin Thromb Hemost. 2009 Sep; 35(6):548-53. PMID: 19787558.
    View in: PubMed
  133. Rose AJ, Ozonoff A, Grant RW, Henault LE, Hylek EM. Epidemiology of subtherapeutic anticoagulation in the United States. Circ Cardiovasc Qual Outcomes. 2009 Nov; 2(6):591-7. PMID: 20031897.
    View in: PubMed
  134. Witt DM, Delate T, McCool KH, Dowd MB, Clark NP, Crowther MA, Garcia DA, Ageno W, Dentali F, Hylek EM, Rector WG. Incidence and predictors of bleeding or thrombosis after polypectomy in patients receiving and not receiving anticoagulation therapy. J Thromb Haemost. 2009 Dec; 7(12):1982-9. PMID: 19719825.
    View in: PubMed
  135. Hylek EM. The need for new oral anticoagulants in clinical practice. J Cardiovasc Med (Hagerstown). 2009 Aug; 10(8):605-9. PMID: 19571764.
    View in: PubMed
  136. Garcia DA, Hylek E. Warfarin pharmacogenetics. N Engl J Med. 2009 Jun 4; 360(23):2474; author reply 2475. PMID: 19494226.
    View in: PubMed
  137. Witt DM, Delate T, Clark NP, Martell C, Tran T, Crowther MA, Garcia DA, Ageno W, Hylek EM. Outcomes and predictors of very stable INR control during chronic anticoagulation therapy. Blood. 2009 Jul 30; 114(5):952-6. PMID: 19439733.
    View in: PubMed
  138. Lopes RD, Becker RC, Garcia D, Hylek EM, Granger CB, Lourenço DM, Nader HB, Maffei FH, Cesena FH, Nicolau JC, Timmerman A, Rocha AT, de Paiva EF, Guimaraes HP, Carvalho AC, D'Amico EA, Moreira-Filho CA, Aldrighi JM, Lopes AC. Highlights from the I international symposium of thrombosis and anticoagulation in internal medicine, October 23-25, 2008, Sao Paulo, Brazil. J Thromb Thrombolysis. 2009 Jul; 28(1):106-16. PMID: 19322521.
    View in: PubMed
  139. Rose AJ, Berlowitz DR, Frayne SM, Hylek EM. Measuring quality of oral anticoagulation care: extending quality measurement to a new field. Jt Comm J Qual Patient Saf. 2009 Mar; 35(3):146-55. PMID: 19326806.
    View in: PubMed
  140. Hylek EM, Rose AJ. Understanding low INR in clinical practice. Thromb Haemost. 2009 Mar; 101(3):417-8. PMID: 19277399.
    View in: PubMed
  141. Freedman JE, Hylek EM. Clopidogrel, genetics, and drug responsiveness. N Engl J Med. 2009 Jan 22; 360(4):411-3. PMID: 19164193.
    View in: PubMed
  142. Hylek EM, Becker RC. Atrial fibrillation and stroke severity: expanding the mechanistic exemplar, clinical phenotype, and goals of anticoagulant pharmacotherapy. Ann Neurol. 2008 Nov; 64(5):480-3. PMID: 19067369.
    View in: PubMed
  143. Rose AJ, Ozonoff A, Berlowitz DR, Henault LE, Hylek EM. Warfarin dose management affects INR control. J Thromb Haemost. 2009 Jan; 7(1):94-101. PMID: 18983486.
    View in: PubMed
  144. Rose AJ, Ozonoff A, Henault LE, Hylek EM. Warfarin for atrial fibrillation in community-based practise. J Thromb Haemost. 2008 Oct; 6(10):1647-54. PMID: 18853483.
    View in: PubMed
  145. Lopes RD, Piccini JP, Hylek EM, Granger CB, Alexander JH. Antithrombotic therapy in atrial fibrillation: guidelines translated for the clinician. J Thromb Thrombolysis. 2008 Dec; 26(3):167-74. PMID: 18807225.
    View in: PubMed
  146. Hylek EM. Oral anticoagulant therapy for patients with atrial fibrillation--an update. Thromb Res. 2008; 123 Suppl 1:S46-9. PMID: 18809205.
    View in: PubMed
  147. Hylek EM, Frison L, Henault LE, Cupples A. Disparate stroke rates on warfarin among contemporaneous cohorts with atrial fibrillation: potential insights into risk from a comparative analysis of SPORTIF III versus SPORTIF V. Stroke. 2008 Nov; 39(11):3009-14. PMID: 18703812.
    View in: PubMed
  148. Clark NP, Witt DM, Delate T, Trapp M, Garcia D, Ageno W, Hylek EM, Crowther MA. Thromboembolic consequences of subtherapeutic anticoagulation in patients stabilized on warfarin therapy: the low INR study. Pharmacotherapy. 2008 Aug; 28(8):960-7. PMID: 18657012.
    View in: PubMed
  149. Hylek EM. Contra: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'. Caveats regarding use of oral anticoagulant therapy among elderly patients with atrial fibrillation. Thromb Haemost. 2008 Jul; 100(1):16-7. PMID: 18612532.
    View in: PubMed
  150. Garcia DA, Witt DM, Hylek E, Wittkowsky AK, Nutescu EA, Jacobson A, Moll S, Merli GJ, Crowther M, Earl L, Becker RC, Oertel L, Jaffer A, Ansell JE. Delivery of optimized anticoagulant therapy: consensus statement from the Anticoagulation Forum. Ann Pharmacother. 2008 Jul; 42(7):979-88. PMID: 18559954.
    View in: PubMed
  151. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun; 133(6 Suppl):160S-198S. PMID: 18574265.
    View in: PubMed
  152. Garcia DA, Hylek E. Reducing the risk for stroke in patients who have atrial fibrillation. Cardiol Clin. 2008 May; 26(2):267-75, vii. PMID: 18406999.
    View in: PubMed
  153. Jagsi R, Tarbell NJ, Henault LE, Chang Y, Hylek EM. The representation of women on the editorial boards of major medical journals: a 35-year perspective. Arch Intern Med. 2008 Mar 10; 168(5):544-8. PMID: 18332302.
    View in: PubMed
  154. Bussey HI, Wittkowsky AK, Hylek EM, Walker MB. Genetic testing for warfarin dosing? Not yet ready for prime time. Pharmacotherapy. 2008 Feb; 28(2):141-3. PMID: 18225960.
    View in: PubMed
  155. Hylek EM, Solarz DE. Dual antiplatelet and oral anticoagulant therapy: increasing use and precautions for a hazardous combination. JACC Cardiovasc Interv. 2008 Feb; 1(1):62-4. PMID: 19393146.
    View in: PubMed
  156. Garcia DA, Regan S, Henault LE, Upadhyay A, Baker J, Othman M, Hylek EM. Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med. 2008 Jan 14; 168(1):63-9. PMID: 18195197.
    View in: PubMed
  157. Hylek EM, Magnani JW. Methodological considerations for interpretation of rates of major haemorrhage in studies of anticoagulant therapy for atrial fibrillation. Europace. 2008 Jan; 10(1):3-5. PMID: 18039690.
    View in: PubMed
  158. Hylek E. DU-176b, an oral, direct Factor Xa antagonist. Curr Opin Investig Drugs. 2007 Sep; 8(9):778-83. PMID: 17729190.
    View in: PubMed
  159. Garcia D, Hylek E. Stroke prevention in elderly patients with atrial fibrillation. Lancet. 2007 Aug 11; 370(9586):460-1. PMID: 17693158.
    View in: PubMed
  160. Evans-Molina C, Regan S, Henault LE, Hylek EM, Schwartz GR. The new Medicare Part D prescription drug benefit: an estimation of its effect on prescription drug costs in a Medicare population with atrial fibrillation. J Am Geriatr Soc. 2007 Jul; 55(7):1038-43. PMID: 17608876.
    View in: PubMed
  161. Fang MC, Go AS, Chang Y, Hylek EM, Henault LE, Jensvold NG, Singer DE. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med. 2007 Aug; 120(8):700-5. PMID: 17679129.
    View in: PubMed
  162. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007 May 29; 115(21):2689-96. PMID: 17515465.
    View in: PubMed
  163. Rose AJ, Sharman JP, Ozonoff A, Henault LE, Hylek EM. Effectiveness of warfarin among patients with cancer. J Gen Intern Med. 2007 Jul; 22(7):997-1002. PMID: 17476542.
    View in: PubMed
  164. Garcia D, Hylek E. A risk model predicted major bleeding in older patients with atrial fibrillation receiving warfarin therapy. Evid Based Med. 2007 Apr; 12(2):57. PMID: 17400649.
    View in: PubMed
  165. Garcia D, Hylek E. A risk model predicted major bleeding in older patients with atrial fibrillation receiving warfarin therapy. ACP J Club. 2007 Mar-Apr; 146(2):52. PMID: 17335175.
    View in: PubMed
  166. Hylek EM. Does preadmission anticoagulation therapy reduce stroke severity in patients with atrial fibrillation? Nat Clin Pract Cardiovasc Med. 2007 Apr; 4(4):186-7. PMID: 17290231.
    View in: PubMed
  167. Fang MC, Go AS, Hylek EM, Chang Y, Henault LE, Jensvold NG, Singer DE. Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study. J Am Geriatr Soc. 2006 Aug; 54(8):1231-6. PMID: 16913990.
    View in: PubMed
  168. Jagsi R, Guancial EA, Worobey CC, Henault LE, Chang Y, Starr R, Tarbell NJ, Hylek EM. The "gender gap" in authorship of academic medical literature--a 35-year perspective. N Engl J Med. 2006 Jul 20; 355(3):281-7. PMID: 16855268.
    View in: PubMed
  169. Hylek EM, D'Antonio J, Evans-Molina C, Shea C, Henault LE, Regan S. Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation. Stroke. 2006 Apr; 37(4):1075-80. PMID: 16527999.
    View in: PubMed
  170. Garcia DA, Hylek EM. Antithrombotic therapy in atrial fibrillation. Clin Geriatr Med. 2006 Feb; 22(1):155-66, x. PMID: 16377472.
    View in: PubMed
  171. Garcia DA, Regan S, Crowther M, Hylek EM. The risk of hemorrhage among patients with warfarin-associated coagulopathy. J Am Coll Cardiol. 2006 Feb 21; 47(4):804-8. PMID: 16487849.
    View in: PubMed
  172. Guyatt G, Gutterman D, Baumann MH, Addrizzo-Harris D, Hylek EM, Phillips B, Raskob G, Lewis SZ, Schünemann H. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force. Chest. 2006 Jan; 129(1):174-81. PMID: 16424429.
    View in: PubMed
  173. Fang MC, Singer DE, Chang Y, Hylek EM, Henault LE, Jensvold NG, Go AS. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation. 2005 Sep 20; 112(12):1687-91. PMID: 16157766.
    View in: PubMed
  174. Garcia D, Regan S, Crowther M, Hughes RA, Hylek EM. Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. Chest. 2005 Jun; 127(6):2049-56. PMID: 15947319.
    View in: PubMed
  175. Fang MC, Chang Y, Hylek EM, Rosand J, Greenberg SM, Go AS, Singer DE. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med. 2004 Nov 16; 141(10):745-52. PMID: 15545674.
    View in: PubMed
  176. Hylek EM. Paracetamol (acetaminophen) and warfarin interaction: unraveling the pivotal role of the vitamin K cycle. Thromb Haemost. 2004 Oct; 92(4):672-3. PMID: 15467892.
    View in: PubMed
  177. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep; 126(3 Suppl):204S-233S. PMID: 15383473.
    View in: PubMed
  178. Go AS, Hylek EM, Chang Y, Phillips KA, Henault LE, Capra AM, Jensvold NG, Selby JV, Singer DE. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA. 2003 Nov 26; 290(20):2685-92. PMID: 14645310.
    View in: PubMed
  179. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, Singer DE. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003 Sep 11; 349(11):1019-26. PMID: 12968085.
    View in: PubMed
  180. Hylek EM. Trends in anticoagulation management across community-based practices in the United States: the Anticoagulation Consortium to Improve Outcomes Nationally (ACTION) study. J Thromb Thrombolysis. 2003 Aug-Oct; 16(1-2):83-6. PMID: 14760219.
    View in: PubMed
  181. Hylek EM. Complications of oral anticoagulant therapy: bleeding and nonbleeding, rates and risk factors. Semin Vasc Med. 2003 Aug; 3(3):271-8. PMID: 15199460.
    View in: PubMed
  182. Hylek EM, Regan S, Henault LE, Gardner M, Chan AT, Singer DE, Barry MJ. Challenges to the effective use of unfractionated heparin in the hospitalized management of acute thrombosis. Arch Intern Med. 2003 Mar 10; 163(5):621-7. PMID: 12622610.
    View in: PubMed
  183. Go AS, Reed GL, Hylek EM, Phillips KA, Liu L, Henault LE, Selby JV, Singer DE. Factor V Leiden and risk of ischemic stroke in nonvalvular atrial fibrillation: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. J Thromb Thrombolysis. 2003 Feb; 15(1):41-6. PMID: 14574075.
    View in: PubMed
  184. Smith EE, Rosand J, Knudsen KA, Hylek EM, Greenberg SM. Leukoaraiosis is associated with warfarin-related hemorrhage following ischemic stroke. Neurology. 2002 Jul 23; 59(2):193-7. PMID: 12136056.
    View in: PubMed
  185. Hylek EM, Regan S, Go AS, Hughes RA, Singer DE, Skates SJ. Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. Ann Intern Med. 2001 Sep 18; 135(6):393-400. PMID: 11560452.
    View in: PubMed
  186. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001 May 9; 285(18):2370-5. PMID: 11343485.
    View in: PubMed
  187. Hylek EM. Oral anticoagulants. Pharmacologic issues for use in the elderly. Clin Geriatr Med. 2001 Feb; 17(1):1-13. PMID: 11270124.
    View in: PubMed
  188. Rosand J, Hylek EM, O'Donnell HC, Greenberg SM. Warfarin-associated hemorrhage and cerebral amyloid angiopathy: a genetic and pathologic study. Neurology. 2000 Oct 10; 55(7):947-51. PMID: 11061249.
    View in: PubMed
  189. Go AS, Hylek EM, Phillips KA, Borowsky LH, Henault LE, Chang Y, Selby JV, Singer DE. Implications of stroke risk criteria on the anticoagulation decision in nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Circulation. 2000 Jul 4; 102(1):11-3. PMID: 10880408.
    View in: PubMed
  190. Hylek EM, Chang YC, Skates SJ, Hughes RA, Singer DE. Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch Intern Med. 2000 Jun 12; 160(11):1612-7. PMID: 10847254.
    View in: PubMed
  191. Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med. 1999 Dec 21; 131(12):927-34. PMID: 10610643.
    View in: PubMed
  192. Hylek EM, Heiman H, Skates SJ, Sheehan MA, Singer DE. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA. 1998 Mar 4; 279(9):657-62. PMID: 9496982.
    View in: PubMed
  193. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med. 1996 Aug 22; 335(8):540-6. PMID: 8678931.
    View in: PubMed
  194. Singer DE, Hylek EM. Optimal oral anticoagulation for patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med. 1995 Nov 30; 333(22):1504. PMID: 7477157.
    View in: PubMed
  195. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med. 1994 Jun 1; 120(11):897-902. PMID: 8172435.
    View in: PubMed
  196. Hylek EM. How the doctor got gagged. JAMA. 1992 Jul 1; 268(1):50-1. PMID: 1472193.
    View in: PubMed
Elaine's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
BU Co-Authors
_
Similar BU People
_
Same Department